Literature DB >> 25903803

Current trends and new frontiers in focal therapy for localized prostate cancer.

Melissa H Mendez1, Daniel Y Joh, Rajan Gupta, Thomas J Polascik.   

Abstract

Prostate cancer (PCa) care is an ever-evolving field. Research and technological developments continue to refine our definitions and management of this disease. Now, with a greater understanding of the natural history of PCa, the prevention of overtreatment has shaped a new era with the adoption of active surveillance (AS) and advancement of focal therapy (FT). Multiparametric magnetic resonance imaging (mpMRI) allows us to define, locate, and monitor cancers in a way never before possible. These capabilities combined with promising results from current prospective studies have changed the face of FT. This review presents the latest developments, current trends, and next steps in FT.

Entities:  

Mesh：

Year:  2015        PMID： 25903803     DOI： 10.1007/s11934-015-0513-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  82 in total

1.  Tumor focality is not associated with biochemical outcome after radical prostatectomy.

Authors:  Viacheslav Iremashvili; Liset Pelaez; Murugesan Manoharan; Kristell Acosta; Daniel L Rosenberg; Mark S Soloway
Journal:  Prostate       Date:  2011-08-31       Impact factor: 4.104

2.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

Authors:  Caroline M A Hoeks; Martijn G Schouten; Joyce G R Bomers; Stefan P Hoogendoorn; Christina A Hulsbergen-van de Kaa; Thomas Hambrock; Henk Vergunst; J P Michiel Sedelaar; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Eur Urol       Date:  2012-02-01       Impact factor: 20.096

3.  African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?

Authors:  Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

4.  Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection.

Authors:  Andrew B Rosenkrantz; Jeffry Neil; Xiangtian Kong; Jonathan Melamed; James S Babb; Samir S Taneja; Bachir Taouli
Journal:  AJR Am J Roentgenol       Date:  2010-02       Impact factor: 3.959

5.  Focal brachytherapy for selected low-risk prostate cancers: a pilot study.

Authors:  Jean-Marc Cosset; Xavier Cathelineau; Georges Wakil; Noelle Pierrat; Olivier Quenzer; Dominique Prapotnich; Eric Barret; François Rozet; Marc Galiano; Guy Vallancien
Journal:  Brachytherapy       Date:  2013-04-16       Impact factor: 2.362

6.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

7.  Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience.

Authors:  Ted Lee; Neil Mendhiratta; Dan Sperling; Herbert Lepor
Journal:  Rev Urol       Date:  2014

8.  Image guided photothermal focal therapy for localized prostate cancer: phase I trial.

Authors:  U Lindner; R A Weersink; M A Haider; M R Gertner; S R H Davidson; M Atri; B C Wilson; A Fenster; J Trachtenberg
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

10.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440
View more
  2 in total

1.  Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging.

Authors:  Christina Sze; Efrat Tsivian; Kae Jack Tay; Ariel A Schulman; Leah G Davis; Rajan T Gupta; Thomas J Polascik
Journal:  BMC Urol       Date:  2019-12-05       Impact factor: 2.264

2.  Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project.

Authors:  M J Scheltema; K J Tay; A W Postema; D M de Bruin; J Feller; J J Futterer; A K George; R T Gupta; F Kahmann; C Kastner; M P Laguna; S Natarajan; S Rais-Bahrami; A R Rastinehad; T M de Reijke; G Salomon; N Stone; R van Velthoven; R Villani; A Villers; J Walz; T J Polascik; J J M C H de la Rosette
Journal:  World J Urol       Date:  2016-09-16       Impact factor: 4.226
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.